This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Valorisation Hsj, Limited Partnership. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Élie Haddad: Innovator in Synthetic Expression Cassettes
Introduction
Élie Haddad is a notable inventor based in Hampstead, CA. He has made significant contributions to the field of biotechnology, particularly in the development of synthetic expression cassettes. His work focuses on enhancing the expression of nucleic acids in specific cell types, which has important implications for medical treatments.
Latest Patents
Haddad holds a patent for "Cell specific transcriptional regulatory sequences and uses thereof." This patent discloses new synthetic expression cassettes that comprise a minimal promoter and a cell-specific enhancer. These innovations allow for the expression of a nucleic acid of interest in one or more specific cell subtypes. The patent also includes vectors and host cells that utilize these synthetic expression cassettes. Furthermore, it outlines methods for expressing nucleic acids, such as those encoding chimeric antigen receptors (CAR), in cells. This technology has potential applications in treating diseases, including cancers and genetic disorders.
Career Highlights
Élie Haddad is associated with Valorisation Hsj, Limited Partnership, where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and the application of biotechnology to solve pressing health issues.
Collaborations
Haddad collaborates with talented individuals in his field, including Panojot Bifsha and Aurélien Colamartino. These partnerships enhance the scope and impact of his research.
Conclusion
Élie Haddad's contributions to synthetic expression cassettes represent a significant advancement in biotechnology. His innovative work has the potential to transform therapeutic approaches for various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile